trending Market Intelligence /marketintelligence/en/news-insights/trending/zV1ZRJMOLcI0-mcOI2u5Sw2 content esgSubNav
In This List

Therapix lays off staff due to insufficient funds

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Therapix lays off staff due to insufficient funds

Therapix Biosciences Ltd. has terminated the employment of all of its staff except interim CEO Ascher Shmulewitz due to a lack of sufficient funds.

CFO Oz Adler and Chief Technologies Officer Adi Zuloff-Shani will remain in their positions until March 30, 2020, as part of their 90-day notice period.

Therapix's remaining directors and officers will continue to seek fundraising opportunities, including the Israel-based medical cannabis company's planned combination with Heavenly Rx Ltd.

In November 2019, Therapix and Destiny Bioscience Global Corp. mutually agreed to discontinue talks on a proposed merger between the two companies.